Companies › TILT Biotherapeutics
2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TILT-123 Oncolytic adenovirus encoding TNFα and IL-2 | – | Phase 1 | Lung Cancer; Metastatic Melanoma; Melanoma; Platinum-refractory Ovarian Carcinoma | Nov 2026 |
| Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 1 | Melanoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06125197 | TILT-123 | Phase 1 | Lung Cancer | Oncology | Jan 2026 |
| NCT06961786 | TILT-123 | Phase 1 | Metastatic Melanoma | Oncology | Nov 2026 |
| NCT05222932 | TILT-123 | Phase 1 | Melanoma | Oncology | Dec 2026 |
| NCT05222932 | Avelumab | Phase 1 | Melanoma | Oncology | Dec 2026 |
| NCT05271318 | TILT-123 | Phase 1 | Platinum-refractory Ovarian Carcinoma | Oncology | Mar 2027 |
AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.